[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-433825-105":59,"doc-detail-433825-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","massive-intra-abdominal-pseudotumor-in-a-patient-with-hemophilia-a-treated-with-emicizumab-a-case-report","Massive Intra-Abdominal Pseudotumor in a Patient With Hemophilia A Treated With Emicizumab - A Case Report","","Hemophilic pseudotumors are a rare complication of bleeding disorders and are more frequent where access to clotting factor concentrates is limited. This case report investigates subcutaneous emicizumab, a newer therapy for hemophilia A, for stabilizing an inoperable pseudotumor in a patient with factor VIII deficiency in an under-resourced setting. The study highlights treatment challenges and the clinical need for alternatives when standard replacement products are scarce, emphasizing outcomes relevant to bleeding control and pseudotumor management.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/massive-intra-abdominal-pseudotumor-in-a-patient-with-hemophilia-a-treated-with-emicizumab-a-case-report/433825/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/massive-intra-abdominal-pseudotumor-in-a-patient-with-hemophilia-a-treated-with-emicizumab-a-case-report/433825.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What condition is described in the case report?","Question",{"text":112,"@type":113},"The report describes a massive intra-abdominal hemophilic pseudotumor in a patient with hemophilia A (factor VIII deficiency).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why was emicizumab considered for this pseudotumor?",{"text":117,"@type":113},"Emicizumab can provide prophylactic hemostatic activity without requiring activated FVIII cofactor function, offering a potential option when standard factor concentrates are limited and the pseudotumor is inoperable.",{"name":119,"@type":110,"acceptedAnswer":120},"What challenges to treatment are highlighted in the introduction?",{"text":121,"@type":113},"The introduction emphasizes limited and sporadic access to clotting factor concentrates in under-resourced settings, along with healthcare access barriers and the risk of cumulative tissue damage when bleeding is not treated promptly.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},433825,1791054474,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Clinical Case Reports  \nCASE REPORT  OPEN ACCESS   \nMassive Intra-Abdominal Pseudotumor in a Patient With Hemophilia A Treated With Emicizumab: A Case Report  \nC. J. Kilach1 | C. Njuguna1 | F. Njuguna1,2  | C. M. Wanjiku1,3 | K. F. Molitor4 | I. A. Janson4 | S. M. Mbunya1,4 |  \nA. D. Shapiro4 | J. Sagar4 | A. Greist4  \n1Academic Model for Provision of Access to Healthcare (AMPATH), Eldoret, Kenya | 2Moi University School of Medicine, Eldoret, Kenya | 3Division of Hematology-Oncology, University of North Carolina, Chapel Hill, North Carolina, USA | 4Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, USA  \nCorrespondence: F. Njuguna ([muigaifes2000@gmail.com](muigaifes2000@gmail.com))  \nReceived: 2 November 2024 | Revised: 3 November 2025 | Accepted: 21 December 2025  \nKeywords: emicizumab | hemophilia A | hemophilic pseudotumor | therapeutic embolization  \nABSTRACT  \nHemophilic pseudotumors, a rare complication of bleeding disorders, are more common in settings with limited access to clotting factor concentrates. Subcutaneous emicizumab, a relatively novel therapy for hemophilia A, was investigated for its ability to stabilize an inoperable pseudotumor in a patient with factor VIII deficiency in an under-resourced setting.  \n1 | Introduction  \nHemophilia is an inherited X-linked recessive bleeding disorder due to mutations in the gene for factor VIII (FVIII) or factor IX (FIX), leading to a deficiency of the respective procoagulant. Although hemophilia primarily affects males, female carriers may have reduced procoagulant levels resulting in a bleeding phenotype. Episodes of hemorrhage into the joints and muscles are the hallmark of hemophilia, yet bleeding occurs in many areas, including vital organs [1] .  \nIn countries with adequate resources, the mainstay of treatment has been intravenous administration of replacement products containing either FVIII or FIX. Therapy may be administered in response to a bleeding event or prophylactically to prevent bleeds. Over the past 30 years, there have been major advancesin the development of treatment products including geneticallyengineered, ultra-pure clotting factor concentrates (CFCs), safe from risk of pathogen transmission. These products are costly, translating in US dollars to thousands per infusion. Most persons with hemophilia (PwH) in financially constrained countries have limited and/or sporadic access to CFCs. These PwHare often dependent on donations prioritized for life- and/or  \nlimb-threatening bleeding. Furthermore, other issues significantly impact access to healthcare services such as racialized status, home location, and economic status within a country [2] . When musculoskeletal bleeds are not treated promptly, cumulative tissue damage may occur leading to loss of function, hemophilic arthropathy, and permanent disability [3] .  \nRepeated bleeding episodes in bone or soft tissue can lead to the development of hemophilic pseudotumors. Most hemophilic pseudotumors have been reported in males with severe or moderate hemophilia in resource-constrained regions and are uncommon in countries with readily available CFCs. Although most pseudotumors begin as an intramuscular hematoma, they may also occur in bone. If the hematoma is inadequately treated and does not resolve completely, it may become organized and encapsulated. The capsule can acquire a blood supply, with the hematoma developing recurrent bleeds resulting in growth overtime, compression, and potential erosion of adjacent structures. Pseudotumors may become partially calcified, erode bony tissue, and result in fractures dependent on location [4] .  \nThere are no standard guidelines for the management of hemophilic pseudotumors. Various therapeutic interventions have  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for","cbCaivxblKYa74qT","https://ap.wps.com/l/cbCaivxblKYa74qT","pdf",792637,"English","# Abstract\n# Introduction\n# Clinical Case","[{\"question\":\"What condition is described in the case report?\",\"answer\":\"The report describes a massive intra-abdominal hemophilic pseudotumor in a patient with hemophilia A (factor VIII deficiency).\"},{\"question\":\"Why was emicizumab considered for this pseudotumor?\",\"answer\":\"Emicizumab can provide prophylactic hemostatic activity without requiring activated FVIII cofactor function, offering a potential option when standard factor concentrates are limited and the pseudotumor is inoperable.\"},{\"question\":\"What challenges to treatment are highlighted in the introduction?\",\"answer\":\"The introduction emphasizes limited and sporadic access to clotting factor concentrates in under-resourced settings, along with healthcare access barriers and the risk of cumulative tissue damage when bleeding is not treated promptly.\"}]","Massive Intra-Abdominal Pseudotumor in a Patient With Hemophilia A Treated With Emicizumab - A Case Report | PDF",1790665631,18]